S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:PHAT

Phathom Pharmaceuticals (PHAT) Stock Forecast, Price & News

$10.63
+0.01 (+0.09%)
(As of 09/22/2023 ET)
Compare
Today's Range
$10.36
$10.80
50-Day Range
$10.62
$15.70
52-Week Range
$5.84
$17.02
Volume
251,132 shs
Average Volume
457,843 shs
Market Capitalization
$603.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.33

Phathom Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
119.5% Upside
$23.33 Price Target
Short Interest
Bearish
11.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.07) to ($4.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

813th out of 963 stocks

Pharmaceutical Preparations Industry

390th out of 458 stocks


PHAT stock logo

About Phathom Pharmaceuticals (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT Price History

PHAT Stock News Headlines

Phathom Pharmaceuticals (NASDAQ:PHAT) Sees Large Volume Increase
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Reflux Testing Products Global Market Report 2023
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
JonesTrading downgrades Impel Pharmaceuticals (IMPL) to a Hold
JonesTrading Keeps Their Buy Rating on Ovid Therapeutics (OVID)
JonesTrading Remains a Buy on Longboard Pharmaceuticals (LBPH)
Phathom Pharmaceuticals (NASDAQ: PHAT)
Stoke Therapeutics (STOK) Gets a Buy from Needham
See More Headlines
Receive PHAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAT Company Calendar

Last Earnings
8/10/2023
Today
9/24/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAT
Fax
N/A
Employees
112
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+119.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-197,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.80) per share

Miscellaneous

Free Float
41,409,000
Market Cap
$603.78 million
Optionable
Not Optionable
Beta
0.45
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Ms. Terrie J. CurranMs. Terrie J. Curran (Age 54)
    Pres, CEO & Director
    Comp: $1.11M
  • Mr. David A. SocksMr. David A. Socks (Age 48)
    Co-Founder & Director
    Comp: $58.78k
  • Dr. Azmi Nabulsi M.D. (Age 63)
    M.P.H., Co-Founder & COO
    Comp: $815.21k
  • Ms. Molly Henderson CPA (Age 52)
    MBA, Chief Financial & Bus. Officer
    Comp: $671.27k
  • Mr. Aditya Kohli Ph.D. (Age 35)
    Co-Founder
  • Mr. Anthony J. Guzzo (Age 50)
    Chief Accounting Officer
  • Mr. Joseph Hand J.D.
    Chief Admin. Officer
  • Mr. Lawrence Miller Esq.
    J.D., Gen. Counsel & Sec.
  • Mr. Tom Harris
    Chief Devel. Sciences Officer
  • Dr. Eckhard Leifke M.D.
    Ph.D., Chief Medical Officer













PHAT Stock - Frequently Asked Questions

Should I buy or sell Phathom Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PHAT shares.
View PHAT analyst ratings
or view top-rated stocks.

What is Phathom Pharmaceuticals' stock price forecast for 2023?

7 brokerages have issued 1 year price targets for Phathom Pharmaceuticals' stock. Their PHAT share price forecasts range from $16.00 to $30.00. On average, they anticipate the company's stock price to reach $23.33 in the next twelve months. This suggests a possible upside of 119.5% from the stock's current price.
View analysts price targets for PHAT
or view top-rated stocks among Wall Street analysts.

How have PHAT shares performed in 2023?

Phathom Pharmaceuticals' stock was trading at $11.22 at the beginning of 2023. Since then, PHAT stock has decreased by 5.3% and is now trading at $10.63.
View the best growth stocks for 2023 here
.

When is Phathom Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our PHAT earnings forecast
.

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.11.

What ETFs hold Phathom Pharmaceuticals' stock?

ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED).

When did Phathom Pharmaceuticals IPO?

(PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager.

What is Phathom Pharmaceuticals' stock symbol?

Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT."

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Medicxi Ventures Management Jersey Ltd (8.62%), Carlyle Group Inc. (8.02%), BlackRock Inc. (4.59%), 683 Capital Management LLC (2.95%), Kennedy Capital Management LLC (2.41%) and Decheng Capital Management III Cayman LLC (1.95%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi, David A Socks, Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran.
View institutional ownership trends
.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phathom Pharmaceuticals' stock price today?

One share of PHAT stock can currently be purchased for approximately $10.63.

How much money does Phathom Pharmaceuticals make?

Phathom Pharmaceuticals (NASDAQ:PHAT) has a market capitalization of $603.78 million. The company earns $-197,720,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis.

How many employees does Phathom Pharmaceuticals have?

The company employs 112 workers across the globe.

How can I contact Phathom Pharmaceuticals?

Phathom Pharmaceuticals' mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The official website for the company is www.phathompharma.com. The company can be reached via phone at 877-742-8466 or via email at ir@phathompharma.com.

This page (NASDAQ:PHAT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -